# Rivastigmine Mini-Tablet for Alzheimer's Disease

> **NCT06828289** · — · NOT_YET_RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 1000 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Rivastigmine Mini-Tablet
- **DRUG:** Donepezil Hydrochloride

## Key facts

- **NCT ID:** NCT06828289
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06828289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06828289, "Rivastigmine Mini-Tablet for Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06828289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*